Education
About Us
Working with TipRanks
Follow Us
Perspective Therapeutics (CATX)
:CATX
RESEARCH TOOLSreports
Total Valuation
Perspective Therapeutics has a market cap or net worth of $268.71M. The enterprise value is $330.00M.
Market Cap$268.71M
Enterprise Value$330.00M
Share Statistics
Perspective Therapeutics has 74,228,330 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding74,228,330
Owned by Insiders2.63%
Owned by Institutions20.45%
Financial Efficiency
Perspective Therapeutics’s return on equity (ROE) is -0.27 and return on invested capital (ROIC) is 3.15%.
Return on Equity (ROE)-0.27
Return on Assets (ROA)-0.23
Return on Invested Capital (ROIC)3.15%
Return on Capital Employed (ROCE)0.03
Revenue Per Employee0.00
Profits Per Employee-574.49K
Employee Count138
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Perspective Therapeutics is -2.59. Perspective Therapeutics’s PEG ratio is -0.24.
PE Ratio-2.59
PS Ratio0.00
PB Ratio6.42
Price to Fair Value0.71
Price to FCF-28.14
Price to Operating Cash Flow-28.84
PEG Ratio-0.24
Income Statement
In the last 12 months, Perspective Therapeutics had revenue of 0.00 and earned -79.28M in profits. Earnings per share was -1.23.
Revenue0.00
Gross Profit0.00
Operating Income10.46M
Pretax Income-81.38M
Net Income-79.28M
EBITDA10.46M
Earnings Per Share (EPS)-1.23
Cash Flow
In the last 12 months, operating cash flow was -18.29M and capital expenditures -54.41M, giving a free cash flow of -72.71M billion.
Operating Cash Flow-18.29M
Free Cash Flow-72.71M
Free Cash Flow per Share-0.98
Dividends & Yields
Perspective Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.28
52-Week Price Change-62.29%
50-Day Moving Average2.78
200-Day Moving Average5.33
Relative Strength Index (RSI)61.32
Average Volume (3m)1.37M
Important Dates
Perspective Therapeutics upcoming earnings date is Aug 8, 2025, After Close (Confirmed).
Last Earnings DateMay 12, 2025
Next Earnings DateAug 8, 2025
Ex-Dividend Date―
Financial Position
Perspective Therapeutics as a current ratio of 12.68, with Debt / Equity ratio of 0.00%
Current Ratio12.68
Quick Ratio12.68
Debt to Market Cap0.01
Net Debt to EBITDA-5.66
Interest Coverage Ratio-217.90
Taxes
In the past 12 months, Perspective Therapeutics has paid -2.10M in taxes.
Income Tax-2.10M
Effective Tax Rate0.03
Enterprise Valuation
Perspective Therapeutics EV to EBITDA ratio is 13.99, with an EV/FCF ratio of -2.01.
EV to Sales0.00
EV to EBITDA13.99
EV to Free Cash Flow-2.01
EV to Operating Cash Flow-8.00
Balance Sheet
Perspective Therapeutics has $226.92M in cash and marketable securities with $4.06M in debt, giving a net cash position of -$222.85M billion.
Cash & Marketable Securities$226.92M
Total Debt$4.06M
Net Cash-$222.85M
Net Cash Per Share-$3.00
Tangible Book Value Per Share$3.74
Margins
Gross margin is 23.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin23.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Perspective Therapeutics is $13.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$13.33
Price Target Upside254.52% Upside
Analyst ConsensusStrong Buy
Analyst Count10
Revenue Growth Forecast―
EPS Growth Forecast―